inotiv - NOTV

NOTV

Close Chg Chg %
0.61 -0.09 -14.03%

Closed Market

0.52

-0.09 (14.03%)

Volume: 2.42M

Last Updated:

Dec 29, 2025, 4:00 PM EDT

Company Overview: inotiv - NOTV

NOTV Key Data

Open

$0.63

Day Range

0.47 - 0.63

52 Week Range

0.47 - 5.67

Market Cap

$20.96M

Shares Outstanding

34.37M

Public Float

30.97M

Beta

4.35

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.22

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

521.40K

 

NOTV Performance

1 Week
 
-8.80%
 
1 Month
 
-34.17%
 
3 Months
 
-55.85%
 
1 Year
 
-87.16%
 
5 Years
 
-95.05%
 

NOTV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About inotiv - NOTV

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

NOTV At a Glance

Inotiv, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906-1382
Phone 1-765-463-4527 Revenue 513.02M
Industry Miscellaneous Commercial Services Net Income -68,625,000.00
Sector Commercial Services 2025 Sales Growth 4.541%
Fiscal Year-end 09 / 2026 Employees 2,046
View SEC Filings

NOTV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.092
Price to Book Ratio 0.366
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 22.846
Enterprise Value to Sales 0.945
Total Debt to Enterprise Value 0.948

NOTV Efficiency

Revenue/Employee 250,744.868
Income Per Employee -33,541.056
Receivables Turnover 5.265
Total Asset Turnover 0.609

NOTV Liquidity

Current Ratio 0.349
Quick Ratio 0.233
Cash Ratio 0.039

NOTV Profitability

Gross Margin 12.68
Operating Margin -6.767
Pretax Margin -17.108
Net Margin -13.377
Return on Assets -8.151
Return on Equity -44.775
Return on Total Capital -11.527
Return on Invested Capital -17.526

NOTV Capital Structure

Total Debt to Total Equity 337.642
Total Debt to Total Capital 77.15
Total Debt to Total Assets 54.52
Long-Term Debt to Equity 34.386
Long-Term Debt to Total Capital 7.857
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Inotiv - NOTV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
547.66M 572.42M 490.74M 513.02M
Sales Growth
+511.19% +4.52% -14.27% +4.54%
Cost of Goods Sold (COGS) incl D&A
421.33M 441.66M 436.69M 447.97M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
49.32M 54.72M 57.12M 55.93M
Depreciation
18.44M 20.04M 22.33M 21.12M
Amortization of Intangibles
30.89M 34.68M 34.79M 34.81M
COGS Growth
+608.73% +4.83% -1.13% +2.58%
Gross Income
126.32M 130.76M 54.05M 65.05M
Gross Income Growth
+318.90% +3.51% -58.66% +20.35%
Gross Profit Margin
+23.07% +22.84% +11.01% +12.68%
2022 2023 2024 2025 5-year trend
SG&A Expense
122.10M 127.32M 97.92M 92.24M
Research & Development
- - - -
-
Other SG&A
122.10M 127.32M 97.92M 92.24M
SGA Growth
+325.85% +4.27% -23.09% -5.79%
Other Operating Expense
1.30M 5.83M 5.92M 7.52M
Unusual Expense
318.28M 72.22M 33.35M (6.10M)
EBIT after Unusual Expense
(315.36M) (74.60M) (83.13M) (28.62M)
Non Operating Income/Expense
(7.39M) (6.62M) (748.00K) (2.56M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
29.70M 43.02M 46.88M 56.59M
Interest Expense Growth
+1,664.94% +44.83% +8.98% +20.71%
Gross Interest Expense
29.70M 43.02M 46.88M 56.59M
Interest Capitalized
- - - -
-
Pretax Income
(352.45M) (124.24M) (130.76M) (87.77M)
Pretax Income Growth
-5,859.91% +64.75% -5.25% +32.88%
Pretax Margin
-64.36% -21.70% -26.65% -17.11%
Income Tax
(15.19M) (19.34M) (21.88M) (19.14M)
Income Tax - Current - Domestic
557.00K 5.46M 203.00K 561.00K
Income Tax - Current - Foreign
1.67M 944.00K 1.19M 1.92M
Income Tax - Deferred - Domestic
(17.41M) (25.37M) (22.97M) (21.32M)
Income Tax - Deferred - Foreign
(13.00K) (374.00K) (298.00K) (304.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(337.26M) (104.90M) (108.89M) (68.63M)
Minority Interest Expense
- (244.00K) 238.00K (440.00K)
Net Income
(337.02M) (105.14M) (108.44M) (68.63M)
Net Income Growth
-3,193.33% +68.80% -3.14% +36.72%
Net Margin Growth
-61.54% -18.37% -22.10% -13.38%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(337.02M) (105.14M) (108.44M) (68.63M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(337.02M) (105.14M) (108.44M) (68.63M)
EPS (Basic)
-13.8383 -4.1005 -4.1876 -2.1147
EPS (Basic) Growth
-1,775.54% +70.37% -2.12% +49.50%
Basic Shares Outstanding
24.35M 25.64M 25.90M 32.45M
EPS (Diluted)
-13.8383 -4.1005 -4.1876 -2.1147
EPS (Diluted) Growth
-1,861.05% +70.37% -2.12% +49.50%
Diluted Shares Outstanding
24.35M 25.64M 25.90M 32.45M
EBITDA
52.25M 52.34M 7.34M 21.21M
EBITDA Growth
+477.52% +0.17% -85.98% +189.07%
EBITDA Margin
+9.54% +9.14% +1.50% +4.13%

Snapshot

Average Recommendation BUY Average Target Price 7.00
Number of Ratings 2 Current Quarters Estimate -0.638
FY Report Date 12 / 2025 Current Year's Estimate -1.999
Last Quarter’s Earnings -0.25 Median PE on CY Estimate N/A
Year Ago Earnings -2.11 Next Fiscal Year Estimate -1.703
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.64 -0.55 -2.00 -1.70
High Estimates -0.55 -0.48 -1.80 -1.63
Low Estimate -0.73 -0.61 -2.20 -1.78
Coefficient of Variance -20.39 -16.17 -14.25 -6.03

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Inotiv - NOTV

Date Name Shares Transaction Value
Feb 26, 2025 Beth A. Taylor Chief Financial Officer 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Adrian P. Hardy Chief Commercial Officer 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 John E. Sagartz Chief Strategy Officer; Director 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 John Gregory Beattie Chief Operating Officer 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Brennan Freeman VP-Finance & Corp. Controller 3,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Jeffrey Arthur Krupp Chief Human Resources Officer 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Andrea Castetter SVP, Gen. Counsel & Secretary 6,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Robert W. Leasure President and CEO; Director 956,592 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.82 per share 3,654,181.44

Inotiv in the News